Merck’s Lipfendra (Enlicitide) Receives Historic FDA Approval as the First Oral PCSK9 Inhibitor

July 16, 2026

Merck Lipfendra approval, enlicitide FDA, oral PCSK9 inhibitor, hypercholesterolemia treatment, new cholesterol drug 2026. In a landmark development for cardiovascular...